The role of the lysophospholipase D autotaxin (ATX) and lysophosphatidic acid (LPA) in cancer is emerging and represents two key players in regulating cancer progression. In this brief review, we will discuss some of our recent findings, which highlight a central role that LPA and its receptor plays in orchestrating melanoma-stroma interactions in the establishment of lung metastases. In particular, we evaluated not only the function of LPA receptors on tumor cells but also their role on host tissues and how they can influence melanoma growth and metastasis. Using the syngeneic B16F10 murine melanoma model, we made three key observations. First, our in vitro findings demonstrate that LPA receptors, specifically LPA2 and LPA5 expressed in B16F10 cells appear to have opposing roles in cell invasion; the former seems to be responsible for the high basal invasion rate of B16F10 cells while the latter is anti-invasive upon exogenous LPA stimulation. Second, we observed a profound reduction in the incidence of pulmonary melanoma metastasis in LPA1-and LPA5-knockout (KO) mice, respectively, when compared to wild-type (WT) mice. Third, no differences in terms of subcutaneous tumor growth between LPA1KO, LPA5KO and WT mice were observed. These findings suggest that LPA receptors exert different functions in melanoma cells versus host tissues in terms of invasion and metastasis.
LPA and cancer
ATX, also known as ectonucleotide pyrophosphatase/ phosphodiesterase family member 2 (ENPP2) is the primary enzyme that is responsible for the production of LPA by cleaving the headgroups of lysophospholipids, primarily lysophosphatidylcholine (LPC). The physiological and pathological effects of LPA are mediated through activation of a series of G protein-coupled receptors (GPCR). At least six of these receptors termed LPA1 to LPA6 have been characterized whereas little is known about the putative LPA GPCRs (GPR87, P2Y10 and GPR35) [1, 2] .
There are many reports of ATX-LPA receptor signaling axis being implicated in various cancers such as breast [3] , ovarian [4] , prostate [5] , hepatocellular carcinoma [6] , glioblastoma multiforme [7] and melanoma [8] . In most cases, overexpression of ATX and/or LPA receptors in these cancers correlates with the degree of malignancy i.e. enhanced invasiveness, chemoresistance and metastatic
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potential of tumors [9, 10] .
Why melanoma?
We and others have made several key observations that corroborate a central role for ATX-LPA receptor signaling axis in melanoma invasion and metastasis. First, studies by Stracke et al. identified ATX in the conditioned media of human A2058 melanoma cells, which potently stimulate cancer cell motility [11] . Subsequent studies demonstrated that it is LPA, the product of ATX that is responsible for mediating melanoma cell migration and proliferation [12] . Moreover, increased ATX expression was detected in metastatic melanoma specimens compared to basal and squamous cell carcinoma, and normal skin [8] . Many efforts have since been made in developing ATX inhibitors and an excellent review on the chemical evolution of these inhibitors can be found in [13] .
Differential roles of LPA receptors in melanoma invasion
The majority of our work is based on a syngeneic model of a highly metastatic B16F10 murine melanoma. When injected intravenously into mice, these highly aggressive B16F10 cells readily metastasized to the lungs. We found that the expression of ATX was strikingly high in these cells and the enzymatic activity of ATX could be readily detected in the conditioned media. Moreover, we demonstrated that the metastatic capacity of B16F10 cells in vivo is, in part, dependent on ATX. In particular, treatment with an ATX inhibitor, BMP22 significantly reduced pulmonary metastasis in mice [14] . These findings prompted us to examine if the LPA receptor signaling axis contributes to the invasive behavior of B16F10 cells.
We found that B16F10 cells predominantly expressed LPA5, LPA2 and LPA6 receptor transcripts. We evaluated the influence of these receptors on cell invasion using a matrigel-coated Boyden chamber assay system. In serum-free conditions, B16F10 cells exhibit a high basal invasion rate across the matrigel layer. However, when exogenous LPA was added as a chemoattractant, basal cell invasion was greatly attenuated. This observation was somewhat perplexing since one would expect exogenous LPA to enhance cell invasion. To examine which LPA receptors was responsible for the inhibitory effect of LPA on B16F10 invasion, we knocked down LPA5 or LPA2, using shRNAand siRNA-directed methods. Interestingly, we noticed that the inhibitory effect of LPA on B16F10 invasion in vitro was relieved upon knockdown of LPA5. An independent study conducted by Jongsma and colleagues also demonstrated a similar anti-migratory effect of LPA5 in these cells. In addition, the authors showed that alkyl-LPA, which is the preferred ligand for LPA5 [15] was 10 fold more potent than acyl-LPA in inhibiting the migration of B16F10 cells [16] . These findings suggest that activation of the LPA5 receptor by high concentrations of acyl-LPA inhibits B16F10 cell invasion.
On the contrary, knockdown of LPA2 but not LPA5 was sufficient to cause a decrease in basal cell invasion. Similar results were obtained using a LPA2 antagonist termed compound 35 developed by Beck and colleagues [17] . Thus, LPA2 appears to mediate the high basal invasion rate of B16F10 cells. Since no exogenous chemoattractant was used in these experiments, one might question what the source of LPA is. Based on evidence that B16F10 cells express and secrete high amounts of ATX, we postulate that these cells might be capable of generating their own pool of LPA for the activation of LPA2. Indeed, we found that treatment of B16F10 cells with the ATX inhibitor BMP22 dose-dependently reduced basal cell invasion. Although we have not measured the levels of LPC in the culture media of B16F10 cells, studies by Umezu-Goto et al., detected considerable amounts of LPC being released into the culture medium of human A2058 melanoma and MDA-MB 231 breast cancer cells [12] . The release of LPC in the culture medium could in turn serve as a substrate for ATX.
B16F10 cells also express the LPA6 receptor. Jongsma and colleagues have evaluated the contributory role of this receptor in B16F10 cell invasion. These authors found that knockdown of LPA6 expression in B16F10 cells did not affect the basal invasion rate or the inhibitory actions of exogenous LPA on cell invasion [16] . Taken together, these results appear to suggest that the differential expression and activation of LPA receptors by acyl-and/or alkyl-LPA might determine the outcome of invasion in B16F10 cells. We further tested this hypothesis by transducing B16F10 cells, which normally do not express LPA1 receptor, with a LPA1 construct. By overexpressing LPA1 receptor in these cells, we were able to shift the LPA-induced invasive response from one that is chemorepulsive (upon activation of LPA5) to one that is pro-invasive. These findings on the pro-invasive role of LPA1 in melanoma cells corroborate the findings of LeBlanc et al. in breast cancer cells [18] .
LPA and the tumor microenvironment
There is a growing appreciation that the host microenvironment of a tumor plays a fundamental role in cancer progression. The notion is that tumor cells are capable of re-educating their host environment to form one that is "permissive", allowing them to evade host immunity, grow and metastasize. Various stromal elements such as endothelial cells, fibroblasts, infiltrating immune cells, and extracellular matrix make up the tumor microenvironment [19] . We reviewed the LPA receptor expression profile particularly in stromal cells of the lung microenvironment and found LPA receptors to be ubiquitously expressed. For example, we determined that primary mouse lung microvascular endothelial cells isolated from C57BL/6 mice predominantly expressed LPA6, LPA1 and LPA4 receptors. Moreover, primary rat alveolar type II-and differentiated type I-epithelial cells, which line the pulmonary alveoli, expressed high levels of LPA2, and moderate levels of LPA6, LPA3 and LPA5. Studies by Tager et al. showed that lung fibroblasts predominantly expressed LPA1, whereas alveolar macrophages expressed LPA5, LPA4 and LPA2. These authors also reported abundant expression of LPA2 and LPA5 in CD4 + and CD8 + T lymphocytes [20] . Based on these findings, we were interested to study if stromal LPA receptors contribute to melanoma progression and metastasis.
The availability of LPA1, LPA2 and LPA5 receptor knockout mice allowed us to address this aim. In our initial experiments, we isolated mesothelial cells from the respective LPA receptor KO mice and performed a transcellular invasion assay [21, 22] . In this model, the isolated mesothelial cells were cultured into a monolayer and served as a cellular barrier towards the invading tumor cells. We chose MM1 rat hepatocarcinoma cells over B16F10 as a source of tumor cells for the transcellular invasion assay with good reason. MM1 are suspension cells; however, they exhibit a distinct flattened morphology when they invade across the endothelial monolayer and remain associated to it. This allows for easy distinction between non-invaded (rounded cells) and invaded cells (flattened morphology). Moreover, the non-invaded floating cells can be removed from the culture medium by gently rinsing the mesothelial monolayer with PBS. Interestingly, we found that mesothelial cell monolayers isolated from LPA1KO mice were more resistant to MM1 cell invasion. On the contrary, no differences in the invasion of MM1 cells were observed across mesothelial cells isolated from WT, LPA2-or LPA5-KO mice.
We were able to recapitulate this observation in HUVEC cells using the LPA1/LPA3 receptor antagonist, Ki16425. In particular, Ki16425 effectively reduced MM1 tumor cell invasion across the HUVEC monolayer. Since MM1 cells predominantly express LPA2 and LPA6 receptors, we presume that Ki16425 is most likely acting on the LPA1 receptors that are expressed in HUVEC cells. Moreover, HUVEC cells lack LPA3 expression, thus suggesting the effect of Ki16425 is mainly via LPA1. These in vitro results seemingly indicate that the lack of LPA1 or the inhibition of this receptor on stromal cells offers some level of protection against tumor cell invasion. To see if these in vitro observations can be translated in vivo, we injected B16F10 cells into the tail vein of WT and LPA1KO mice, respectively, and quantified lung metastases at day 21. We found that LPA1KO mice had significantly fewer B16F10 lung metastases when compared to WT mice. Once again, these results can be recapitulated using Ki16425. Treatment with Ki16425 effectively reduced the number of lung nodules in WT mice inoculated with B16F10 cells. Because B16F10 cells lack LPA1 and LPA3 expression, we postulate that the effect of Ki16425 in reducing lung metastasis is mostly due to inhibition of LPA1 receptors in host cells.
When we extended these in vivo studies to include the LPA2-and LPA5-KO mice, we found that the extent of B16F10 lung metastasis was the same between LPA2KO mice and their WT counterparts. Intriguingly, lung metastasis was almost completely abolished in the LPA5KO mice. This was the first demonstration that the homing of B16F10 melanoma cells to the lungs and seeding of metastases is substantially reduced by the absence of host LPA1 and almost completely reduced by the absence of LPA5. We also questioned whether host LPA receptor affects the subcutaneous growth of B16F10 in vivo. We found that neither tumor volume nor mass showed significant differences in the respective LPA KO and WT mice, suggesting that deletion of host LPA1, LPA2 or LPA5 have limited effect on local tumor growth.
What's next?
Although our study demonstrates that host LPA receptors, specifically LPA1 and LPA5 are critical in supporting the establishment of lung metastasis, several key questions remain to be addressed: which step of the metastatic cascade is affected by host LPA1 or LPA5 receptors? Which stromal elements are involved in the process? In an attempt to address some of these questions, we performed preliminary experiments to examine the early distribution of fluorescently labeled GFP-tagged B16F10 cells in mice at 24 hour post-inoculation. Using fluorescence microscopy to image the GFP-B16F10 cells on the isolated lung surface, we found that fewer GFP-B16F10 cells were seen on the lung surfaces of LPA1-and LPA5-KO mice, when compared to WT mice. On the contrary, no differences were observed in the degree of GFP-B16F10 distribution in the lung surfaces of WT and LPA2KO mice. These data seemingly suggest that deletion of host LPA1 or LPA5 probably affects the metastatic cascade at an early time point. For example, an impaired tumor-platelet interaction, tumor-macrophage interaction, or tumor-endothelial cell interaction or adhesion might be involved. On the basis of this, together with earlier results demonstrating that mesothelial cells isolated from LPA1KO mice were more resistant to tumor cell invasion and that primary mouse lung microvascular endothelial cells predominantly express LPA1, we postulate that the deletion of host LPA1 receptor most likely affects the tumor-endothelial interaction.
In support of this, several studies have demonstrated a critical role for LPA in regulating endothelial barrier function. In particular, studies by Amerongen et al. showed that LPA was capable of disrupting the endothelial barrier and as a result, increasing vascular permeability [23] . In addition, Tager and colleagues found that the LPA1 receptor was responsible for the increase in vascular leakage following tissue injury in a mouse model of pulmonary fibrosis [20] . These findings certainly warrant for more studies to be conducted to validate the involvement of endothelial LPA1 receptors, especially in the context of tumor-endothelial interaction, adhesion and invasion.
On the other hand, what accounts for the reduced GFP-B16F10 distribution on the lung surfaces of LPA5KO mice at early time points and the finding that lung metastasis was almost completely abolished at day 21 remains unknown. Nonetheless, we postulate that host LPA5 might affect the homing of metastasizing B16F10 cells in a different manner from that of host LPA1 based on two key findings. First, primary mouse lung microvascular endothelial cells lack LPA5 expression. Second, the rate of MM1 cell invasion across the isolated mesothelial monolayer was the same between LPA5KO and WT mice. A recent study by Oda et al. may provide some indication as to what might be happening in LPA5KO mice. These authors showed that cytotoxic CD8 + T cells, which are the subset of immune cells responsible for tumor immunosurveillance, predominantly express LPA5 receptor. Activation of LPA5 on CD8 + T cells inhibited T cell activation and proliferation, and as a result, allows for tumor cells to evade the host immunity. Moreover, the authors elegantly demonstrated that transfer of naïve LPA5
-/-tumor-specific T cells successfully reduced the growth of established melanoma tumors in WT mice [24] . Taken together, these findings suggest a new and important role for LPA5 in the regulation of host immunity towards cancer cells. Apart from cytotoxic CD8 + T cells, interaction of tumor cells with platelets is also an important step in the metastatic cascade. In particular, studies by Boucharaba et al., showed that interaction of MDA-MB 231 breast cancer cells with platelets caused an increased in LPA production, which subsequently drove the formation of osteolytic bone metastasis in mice [25] . In view of this, a role for LPA5 in mediating platelet activation has been reported [15] , thus it would be interesting to examine the effect of LPA5 knockdown in platelets in terms of LPA production and tumor-platelet interaction.
The findings from our study points to a new direction in which the understanding of stromal LPA receptors in the tumor microenvironment is equally as important as studying LPA receptors on the tumor cells. The major focus from now on would be to elucidate the mechanism(s) involved in the seeding of metastasizing tumor cells by host LPA receptors and to pinpoint the stromal elements that are implicated in this process.
